Literature DB >> 2422080

Plasmodium falciparum transmission blocking monoclonal antibodies recognize monovalently expressed epitopes.

A N Vermeulen, W F Roeffen, J B Henderik, T Ponnudurai, P J Beckers, J H Meuwissen.   

Abstract

Target proteins of transmission blocking monoclonal antibodies (MoAbs) are present on the surface of Plasmodium falciparum macrogametes with Mr of 48,000 and 45,000 and on the surface of developing ookinetes with Mr of 25,000. Other MoAbs directed against the same proteins were not able to reduce the number of oocysts in mosquitoes. A combination of a blocking MoAb with a non-blocking one potentiated the transmission blocking effect. This implies that at least two different epitopes are present on the target antigens. This was confirmed using a sandwich immunoradiometric assay. The results demonstrated that on the 48/45 kD proteins as well as on the 25 kD protein a "blocking" and a "non-blocking" epitope exist which are not repeated anywhere else in the molecule.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2422080

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  16 in total

1.  In vitro generation of Plasmodium falciparum ookinetes.

Authors:  Viengngeun Bounkeua; Fengwu Li; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

2.  Naturally occurring antibodies to an epitope on Plasmodium falciparum gametes detected by monoclonal antibody-based competitive enzyme-linked immunosorbent assay.

Authors:  P M Graves; R A Wirtz; R Carter; T R Burkot; M Looker; G A Targett
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

Review 3.  The s48/45 six-cysteine proteins: mediators of interaction throughout the Plasmodium life cycle.

Authors:  Silvia A Arredondo; Stefan H I Kappe
Journal:  Int J Parasitol       Date:  2016-11-27       Impact factor: 3.981

4.  Targeting molecular interactions essential for Plasmodium sexual reproduction.

Authors:  Joel Vega-Rodriguez; Davinia Perez-Barreto; Antonio Ruiz-Reyes; Marcelo Jacobs-Lorena
Journal:  Cell Microbiol       Date:  2015-05-29       Impact factor: 3.715

5.  Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230.

Authors:  J Healer; D McGuinness; P Hopcroft; S Haley; R Carter; E Riley
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

6.  Structure of the Plasmodium 6-cysteine s48/45 domain.

Authors:  Silvia A Arredondo; Mengli Cai; Yuki Takayama; Nicholas J MacDonald; D Eric Anderson; L Aravind; G Marius Clore; Louis H Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

7.  Correctly folded Pfs48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice.

Authors:  Nikolay S Outchkourov; Will Roeffen; Anita Kaan; Josephine Jansen; Adrian Luty; Danielle Schuiffel; Geert Jan van Gemert; Marga van de Vegte-Bolmer; Robert W Sauerwein; Hendrik G Stunnenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

8.  The Plasmodium bottleneck: malaria parasite losses in the mosquito vector.

Authors:  Ryan C Smith; Joel Vega-Rodríguez; Marcelo Jacobs-Lorena
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-08       Impact factor: 2.743

9.  Global genetic diversity of the Plasmodium vivax transmission-blocking vaccine candidate Pvs48/45.

Authors:  Andres F Vallejo; Nora L Martinez; Alejandra Tobon; Jackeline Alger; Marcus V Lacerda; Andrey V Kajava; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Malar J       Date:  2016-04-12       Impact factor: 2.979

10.  Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants.

Authors:  Will Roeffen; Michael Theisen; Marga van de Vegte-Bolmer; GeertJan van Gemert; Theo Arens; Gorm Andersen; Michael Christiansen; Laxman Sevargave; Shrawan Kumar Singh; Swarnendu Kaviraj; Robert Sauerwein
Journal:  Malar J       Date:  2015-11-09       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.